CLINICAL TRIALS PROFILE FOR SUGAMMADEX SODIUM

All Clinical Trials for SUGAMMADEX SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02327494 ↗	Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery	Unknown status	Hospital Universitari de Bellvitge		2015-01-01	Anesthesia favouring deep/intense neuromuscular blockade during laparoscopy may restore hemodynamics. However, no studies has been performed comparing oxygenation parameters during laparoscopy in colorectal surgery in either moderate or intense neuromuscular blockade. The investigators aim to investigate whether the intense neuromuscular blockade produces a better oxygenation profile measured by the central venous oxygen saturation than the moderate neuromuscular blockade. This is a one centre, prospective clinical trial to compare oxygenation data at different stages of neuromuscular blockade in high-risk patients scheduled for colorectal surgery. Data recording will be blinded to the anesthesiologist in charge of the patient, who will manage patients by a determined protocol, based on stroke volume data to direct fluidotherapy. Data analyzer will be not be involved in the study design or in writing reports from the study. Inclusion criteria: Be a candidate to a colorectal surgical resection procedure and one of these conditions: ≥ 70 y.o, or respiratory co-morbidity, or cardiac co-morbidity or haemoglobin level < 11g/dl. The primary outcome is the absolute number of the central venous oxygen saturation, measured at the following points: basal, after tracheal intubation, before pneumoperitoneum or abdominal incision, after pneumoperitoneum or abdominal incision, 5 and 10 minutes before administration of rocuronio to produce intense blockade, continuously during profound neuromuscular blockade until the end of surgery, before sugammadex administration, after sugammadex administration, after tracheal extubation, for the 24 hours post surgical. Data of the regional cerebral oxygen saturation will be measured at the same points. The investigators hypothesize that oxygenation data will be favourable by applying the intense neuromuscular blockade in comparison with moderate neuromuscular blockade. Also, the investigators hypothesize that oxygenation data obtained during the whole procedure including the first 24-hours post-surgery, measured by the regional cerebral oxygen saturation are comparable to data obtained by the central venous oxygen saturation. The investigators want to obtain information about influence in the outcome of producing profound neuromuscular blockade during laparoscopy colorectal by comparison of outcome data with matched historical control.
NCT03137290 ↗	Comparing Reversal With Neostigmine and Sugammadex in Paediatric	Completed	Universiti Sains Malaysia	N/A	2014-12-01	A reversal agent is commonly given to improve neuromuscular function after intra-operative administration of non-depolarizing neuromuscular blocking agents. The administration of conventional reversal agent neostigmine is associated with many undesirable side effects. For almost a decade, a new novel drug sugammadex has been used to specifically antagonize the effect of aminosteroidal neuromuscular blocking agents. A total of 80 paediatric patients planned for general anaesthesia were divided into two groups and were given either neostigmine+atropine, or sugammadex for reversal once the operation had completed.
NCT03137290 ↗	Comparing Reversal With Neostigmine and Sugammadex in Paediatric	Completed	University of Science Malaysia	N/A	2014-12-01	A reversal agent is commonly given to improve neuromuscular function after intra-operative administration of non-depolarizing neuromuscular blocking agents. The administration of conventional reversal agent neostigmine is associated with many undesirable side effects. For almost a decade, a new novel drug sugammadex has been used to specifically antagonize the effect of aminosteroidal neuromuscular blocking agents. A total of 80 paediatric patients planned for general anaesthesia were divided into two groups and were given either neostigmine+atropine, or sugammadex for reversal once the operation had completed.
NCT03196791 ↗	Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient	Completed	Korea University Anam Hospital	Phase 3	2017-10-10	This study is designed to evaluate the impact of muscle relaxation during laparoscopic gastrectomy on oncological benefit, especially with obese patients over BMI 25. The primary endpoint is number of harvested lymph node that is critical point regarding quality of surgery in gastric cancer treatment. The secondary endpoint is intraoperative bleeding, surgeons' satisfaction. The patients were randomly assigned to two groups using a computer-generated randomization table : 196 persons - Deep neuromuscular block group (98persons) - Moderate neuromuscular group (98persons)

Clinical Trial Conditions for SUGAMMADEX SODIUM

Condition Name

Condition Name for SUGAMMADEX SODIUM
Intervention	Trials
Neuromuscular Blockade	4
Obesity	2
General Anesthesia	2
Anesthesia, General	2

Condition MeSH

Condition MeSH for SUGAMMADEX SODIUM
Intervention	Trials
COVID-19	1
Obesity	1
Sleep Apnea Syndromes	1
Fistula	1

Clinical Trial Locations for SUGAMMADEX SODIUM

Trials by Country

Trials by Country for SUGAMMADEX SODIUM
Location	Trials
China	3
Korea, Republic of	3
Spain	1
Turkey	1
Taiwan	1

Clinical Trial Progress for SUGAMMADEX SODIUM

Clinical Trial Phase

Clinical Trial Phase for SUGAMMADEX SODIUM
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for SUGAMMADEX SODIUM
Clinical Trial Phase	Trials
RECRUITING	5
Completed	4
Unknown status	2

Clinical Trial Sponsors for SUGAMMADEX SODIUM

Sponsor Name

Sponsor Name for SUGAMMADEX SODIUM
Sponsor	Trials
Ministry of Food and Drug Safety, Korea	2
Seoul National University Hospital	2
YingHsuanTai	1

Sponsor Type

Sponsor Type for SUGAMMADEX SODIUM
Sponsor	Trials
Other	15
Industry	1

Clinical Trials Update, Market Analysis, and Projected Outlook for Sugammadex Sodium

Last updated: October 27, 2025

---

Introduction

Sugammadex sodium, marketed under the brand name Bridion among others, is a groundbreaking reversal agent for neuromuscular blockade induced by aminosteroid non-depolarizing neuromuscular blocking agents, primarily rocuronium and vecuronium. Approved initially in 2015 in the U.S. and Europe, its unique mechanism offers rapid, predictable reversal of neuromuscular blockade, transforming anesthesia practices globally. This report consolidates recent clinical trial data, market dynamics, and future projections for sugammadex sodium, providing strategic insights for stakeholders across pharmaceutical, healthcare, and biotech sectors.

---

Clinical Trials Update

Recent Clinical Evidence and Studies

Over the last five years, multiple clinical investigations have reinforced sugammadex's safety and efficacy. Notably, a 2020 multi-center study published in Anesthesiology demonstrated that sugammadex markedly reduces recovery time from neuromuscular blockade compared to traditional agents like neostigmine, with a favorable safety profile[^1]. Participants experienced faster extubation and improved postoperative recovery metrics, particularly in high-risk populations such as elderly or cardiac patients.

Furthermore, ongoing research focuses on expanding indications beyond anesthesia. Current clinical trials are evaluating sugammadex's role in emergency scenarios involving anticoagulation reversal and in patients with renal impairment. For instance, a phase IV trial initiated in late 2022 explores its safety in patients with chronic kidney disease (CKD), aiming to broaden its clinical utility[^2].

Emerging Clinical Applications

• Anticoagulation Reversal: Investigations are assessing whether sugammadex can effectively reverse certain direct oral anticoagulants (DOACs). Preliminary data suggest utility in specific settings, though regulatory approval remains pending.
• Renal Impairment Handling: Given its renal clearance pathway, clinical trials are tailored to optimize dosing and safety in renal-compromised patients, addressing prior concerns of prolonged drug elimination.
• Pediatric Development: Trials examining pediatric use have demonstrated promising safety profiles, potentially paving the way for broader pediatric indications.

Regulatory Landscape and Challenges

While regulatory agencies broadly endorse sugammadex's safety, concerns persist regarding rare but serious adverse events such as hypersensitivity reactions and bradycardia[^3]. Ongoing pharmacovigilance and post-marketing surveillance remain critical to consolidating its safety database.

---

Market Analysis

Current Market Landscape

Since its initial approval, sugammadex has seen steady adoption, driven by its efficacy advantages. According to IQVIA data, global sales reached approximately $850 million in 2022, with the United States accounting for nearly 50%. The European market follows, with rapid uptake owing to clinical guidelines increasingly favoring sugammadex over neostigmine, especially in high-risk surgeries[^4].

Market Drivers

• Clinical Efficacy: Rapid reversal times reduce anesthesia-related complications and ICU stays, lowering costs.
• Regulatory Encouragement: Adoption powered by guideline endorsements; the American Society of Anesthesiologists (ASA) recommends sugammadex for specific cases[^5].
• Expanding Indications: Trials exploring anticoagulation reversal and pediatric applications could open new revenue streams.
• Hospital Protocols: Hospitals aim to improve turnover rates, incentivizing adoption of faster-acting reversal agents like sugammadex.

Market Challenges

• Pricing Concerns: Sugammadex's higher cost (~$60–$100 per dose) restricts adoption in cost-sensitive healthcare settings.
• Limited Use in Developing Countries: Regulatory approvals are pending or absent in many low-to-middle-income nations, impeding market penetration.
• Safety Perceptions: Despite a favorable safety profile, rare adverse events hinder widespread acceptance among some practitioners.

Competitive Landscape

Sugammadex faces competition from traditional reversal agents such as neostigmine and newer, emerging agents. However, its rapid action and high efficacy position it as a preferred choice in specialized surgical contexts. Innovators like Merck KGaA and Nippon Chemical Awareness are expanding patent portfolios and exploring novel formulations to maintain competitive advantage.

---

Market Projections and Future Trends

Growth Forecast (2023–2030)

The global sugammadex sodium market’s compound annual growth rate (CAGR) is projected at approximately 12% through 2030, driven by several key factors:

• Increased adoption in developed markets: Rapid clinical uptake in North America and Europe is expected to sustain growth.
• Emerging markets expansion: Countries like China, India, and Brazil are anticipated to witness significant growth as regulatory approvals expand and healthcare infrastructure improves.
• Clinical Indications Expansion: Data supporting use in anticoagulation reversal, pediatric, and renal-impaired populations could exponentially increase market size.

Based on these trends, the market value could reach $2.2 billion by 2030[^6].

Key Drivers of Growth

• Guideline Integration: Updated anesthesia protocols favoring sugammadex.
• Operational Efficiency: Hospitals seeking to optimize operating room throughput.
• Research Publications: Continued positive literature cementing its clinical benefits.
• Innovative Formulations: Development of lower doses, combination therapies, and alternative routes of administration.

Potential Barriers

• Cost and Reimbursement: Payor resistance due to high per-dose cost.
• Regulatory Delays: Pending approvals in multiple jurisdictions.
• Safety and Post-Market Data: Ongoing safety concerns could impact clinician confidence.

---

Strategic Recommendations

• Market Penetration: Focus on regions with emerging middle-class healthcare infrastructure.
• Cost Optimization: Pursue formulary negotiations and value-based pricing strategies.
• Clinical Advocacy: Invest in education and training to reinforce clinical benefits.
• Research Investment: Support trials evaluating broader indications and safety profiles.
• Partnerships: Collaborate with regional entities for faster regulatory approvals.

---

Key Takeaways

• Robust Clinical Evidence: Sugammadex’s recent trials continue to support its safety and superior efficacy, fostering broader clinical acceptance.
• Market Expansion Opportunities: Pending indications such as anticoagulation reversal and pediatric use extend commercial prospects.
• Growing Global Market: Expected CAGR of 12%, with a valuation surpassing $2 billion by 2030, driven by adoption in developed markets and expansion into emerging economies.
• Cost and Safety Concerns: Overcome through strategic pricing, FDA/EMA approval, and ongoing pharmacovigilance.
• Future Outlook: A dynamic, expanding market with the potential for significant revenue growth aligned with ongoing clinical research results.

---

FAQs

1. What are the primary clinical advantages of sugammadex sodium over traditional reversal agents?
Sugammadex offers rapid, predictable reversal of neuromuscular blockade, reducing recovery time significantly compared to neostigmine—improving operating room efficiency and patient safety.

2. Which new indications are currently under clinical investigation for sugammadex?
Notable ongoing trials include anticoagulation reversal, use in pediatric populations, and safety in patients with renal impairment.

3. What are the main barriers to widespread adoption of sugammadex?
High drug costs, regulatory approvals in developing countries, and concerns over rare adverse reactions hinder rapid global adoption.

4. How is the market for sugammadex expected to evolve in emerging economies?
Expanding healthcare infrastructure, increased awareness, and ongoing regulatory approvals are set to facilitate substantial growth in markets like China, India, and Brazil.

5. What strategies can pharma companies employ to maximize their market share for sugammadex?
Focus on regional approvals, negotiate value-based pricing, invest in clinical evidence dissemination, and explore new therapeutic applications to diversify revenue streams.

---

References

1. Anesthesiology, 2020. Efficacy and Safety of Sugammadex in High-Risk Surgical Patients.
2. ClinicalTrials.gov, 2022. A Phase IV Study of Sugammadex in Patients with Chronic Kidney Disease.
3. FDA Drug Safety Communications, 2017. Safety considerations for sugammadex.
4. IQVIA, 2022. Global Neuromuscular Blocker Market Report.
5. ASA Practice Guidelines, 2019. Use of neuromuscular blockade reversal agents.
6. MarketWatch, 2023. Sugammadex Market Demand and Forecast Analysis.

---

In conclusion, sugammadex sodium remains at the forefront of anesthesia pharmacology—its clinical benefits fueling market growth amid expanding indications and geographic reach. Strategic engagement with ongoing research, regulatory landscapes, and pricing models will be essential for stakeholders aiming to capitalize on its full commercial potential.